Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea

Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea

In this study we will prospectively analyze the benefit of inhaled furosemide for preterm and term neonates with Transient Tachypnoea.

In this study we will prospectively analyze the benefit of inhaled furosemide for preterm and term neonates with transient Tachypnoea. Patients received nebulised Furosemide iv solution 1 mg/kg or nebulised 0,9% saline (4x/d) under blind conditions in random order so long as need a CPAP-treatment but max. 3 days. 20 Patient will be treating.

The benefit will be measured as reduction of dyspnea, respiratory rate, oxygen demand and time on CPAP.

Inclusion Criteria:

• Neonates with 35+0-39+0 GA on the first day of life with the clinical diagnosis of Transient Tachypnoea
• The need for CPAP >6 h to obtain the oxygen saturation >92%
• Written informed consent of parent/guardian

Exclusion Criteria:

• Systemic infection
• Intubation and mechanical ventilation before Inclusion in the trail
• Malformation and any other several disease with disturb of respiratory
• Subjects participating in other clinical trials